289 related articles for article (PubMed ID: 14576424)
1. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
2. Genomics. After the gold rush: gene firms reinvent themselves.
Gura T
Science; 2002 Sep; 297(5589):1982-4. PubMed ID: 12242421
[No Abstract] [Full Text] [Related]
3. Open-access public-private partnerships to enable drug discovery--new approaches.
Müller S; Weigelt J
IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
[TBL] [Abstract][Full Text] [Related]
4. What's next in translational medicine?
Littman BH; Di Mario L; Plebani M; Marincola FM
Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
[TBL] [Abstract][Full Text] [Related]
5. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
6. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
7. Private sector contributions to pharmaceutical science: thirty-five summary case histories.
Zycher B; DiMasi JA; Milne CP
Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102
[TBL] [Abstract][Full Text] [Related]
8. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
9. Judging public health research: epistemology, public health and the law.
Wynia MK
Am J Bioeth; 2005; 5(6):4-7. PubMed ID: 16282101
[No Abstract] [Full Text] [Related]
10. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
11. A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception.
Hoffman DC
Cornell Law Rev; 2004 May; 89(4):993-1043. PubMed ID: 15174465
[No Abstract] [Full Text] [Related]
12. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
13. Global health. Public-private partnerships proliferate.
Cohen J
Science; 2006 Jan; 311(5758):167. PubMed ID: 16410497
[No Abstract] [Full Text] [Related]
14. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
15. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
16. In search of a compromised solution to the problem arising from patenting biomedical research tools.
Derzko NM
Santa Clara Comput High Technol Law J; 2004; 20(2):347-410. PubMed ID: 16493840
[No Abstract] [Full Text] [Related]
17. The AMPPA network as a successful model for public-private or private-private partnership.
Diczfalusy E; Fathalla M; Habenicht UF; Stock G
Mol Cell Endocrinol; 2004 Mar; 216(1-2):1-4. PubMed ID: 15109738
[TBL] [Abstract][Full Text] [Related]
18. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
19. Gold in the ivory tower: equity rewards of outlicensing.
Edwards M; Murray F; Yu R
Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
[TBL] [Abstract][Full Text] [Related]
20. New ethical requirements at the NIH: implications for CIHR and Canada.
Bernstein A
CMAJ; 2005 Aug; 173(4):353-4. PubMed ID: 16103503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
